Literature DB >> 34346026

Novel role of long non-coding RNAs in autoimmune cutaneous disease.

Anastasiya Muntyanu1, Michelle Le1, Zainab Ridha2, Elizabeth O'Brien1, Ivan V Litvinov1, Philippe Lefrançois1, Elena Netchiporouk3.   

Abstract

Systemic autoimmune rheumatic diseases (SARDs) are a heterogeneous group of chronic multisystem inflammatory disorders that are thought to have a complex pathophysiology, which is not yet fully understood. Recently, the role of non-coding RNAs, including long non-coding RNA (lncRNA), has been of particular interest in the pathogenesis of SARDs. We aimed to summarize the potential roles of lncRNA in SARDs affecting the skin including, systemic sclerosis (SSc), dermatomyositis (DM) and cutaneous lupus erythematosus (CLE). We conducted a narrative review summarizing original articles published until July 19, 2021, regarding lncRNA associated with SSc, DM, and CLE. Several lncRNAs were hypothesized to play an important role in disease pathogenesis of SSc, DM and CLE. In SSc, Negative Regulator of IFN Response (NRIR) was thought to modulate Interferon (IFN) response in monocytes, anti-sense gene to X-inactivation specific transcript (TSIX) to regulate increased collagen stability, HOX transcript antisense RNA (HOTAIR) to increase numbers of myofibroblasts, OTUD6B-Anti-Sense RNA 1 to decrease fibroblast apoptosis, ncRNA00201 to regulate pathways in SSc pathogenesis and carcinogenesis, H19X potentiating TGF-β-driven extracellular matrix production, and finally PSMB8-AS1 potentiates IFN response. In DM, linc-DGCR6-1 expression was hypothesized to target the USP18 protein, a type 1 IFN-inducible protein that is considered a key regulator of IFN signaling. Additionally, AL136018.1 is suggested to regulate the expression Cathepsin G, which increases the permeability of vascular endothelial cells and the chemotaxis of inflammatory cells in peripheral blood and muscle tissue in DM. Lastly, lnc-MIPOL1-6 and lnc-DDX47-3 in discoid CLE were thought to be associated with the expression of chemokines, which are significant in Th1 mediated disease. In this review, we summarize the key lncRNAs that may drive pathogenesis of these connective tissue diseases and could potentially serve as therapeutic targets in the future.
© 2021. The International CCN Society.

Entities:  

Keywords:  Cutaneous lupus erythematosus; Dermatomyositis; LncRNA; Systemic sclerosis

Year:  2021        PMID: 34346026     DOI: 10.1007/s12079-021-00639-x

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  104 in total

Review 1.  Epigenetic factors as drivers of fibrosis in systemic sclerosis.

Authors:  Christina Bergmann; Jörg Hw Distler
Journal:  Epigenomics       Date:  2017-03-27       Impact factor: 4.778

2.  Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes.

Authors:  Mai A Abd-Elmawla; Mariam Hassan; Yumn A Elsabagh; Alshaimaa Rezk L R Alnaggar; Mahmoud A Senousy
Journal:  Cytokine       Date:  2020-05-13       Impact factor: 3.861

Review 3.  IL-19 as a potential therapeutic in autoimmune and inflammatory diseases.

Authors:  Yasu-Taka Azuma; Hidemitsu Nakajima; Tadayoshi Takeuchi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

4.  Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.

Authors:  Swati Bhattacharyya; Kathleen Kelley; Denisa S Melichian; Zenshiro Tamaki; Feng Fang; Yunyun Su; Gilbert Feng; Richard M Pope; G R Scott Budinger; Gökhan M Mutlu; Robert Lafyatis; Timothy Radstake; Carol Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2012-11-07       Impact factor: 4.307

Review 5.  Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.

Authors:  Swati Bhattacharyya; John Varga
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

6.  Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.

Authors:  C M Black; A J Silman; A I Herrick; C P Denton; H Wilson; J Newman; L Pompon; X Shi-Wen
Journal:  Arthritis Rheum       Date:  1999-02

Review 7.  Systemic sclerosis.

Authors:  Yannick Allanore; Robert Simms; Oliver Distler; Maria Trojanowska; Janet Pope; Christopher P Denton; John Varga
Journal:  Nat Rev Dis Primers       Date:  2015-04-23       Impact factor: 52.329

Review 8.  Epigenetics and pathogenesis of systemic sclerosis; the ins and outs.

Authors:  Saeed Aslani; Soheila Sobhani; Farhad Gharibdoost; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Hum Immunol       Date:  2018-01-09       Impact factor: 2.850

Review 9.  USP18 - a multifunctional component in the interferon response.

Authors:  Anja Basters; Klaus-Peter Knobeloch; Günter Fritz
Journal:  Biosci Rep       Date:  2018-11-15       Impact factor: 3.840

Review 10.  Targeting Costimulatory Pathways in Systemic Sclerosis.

Authors:  Gonçalo Boleto; Yannick Allanore; Jérôme Avouac
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

View more
  2 in total

1.  Modeling the microenvironment special issue.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2022-03-29       Impact factor: 5.782

Review 2.  Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis.

Authors:  Jiangfan Yu; Rui Tang; Ke Ding
Journal:  Int J Gen Med       Date:  2022-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.